The Future of Medical Devices

Pharmaceutical and Biomedical Project Management in a Changing Global Environment

Volumn , Issue , 2010, Pages 347-357

  Kirschner, Ronald L ^a  

^a Heartland Angels   (United States)

Author keywords

BMI project management trends future of medical devices; Overarching value shift towards renewable or "green" technologies; Regulatory approval processes new devices, driven by present trend of combining therapeutics with companion diagnostic assays (Theranostics)

Indexed keywords

EID: 84860607319     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470636930.ch17     Document Type: Chapter

References (11)

1. http://www.fda.gov/oc/history/default.htm .
2. http://www.fda.gov/CDRH/DEVADVICE/312.html .
3. Peters , R. 2008 . Drug Discovery and Development , 10 ( 11 ) November issue, 16-21 .
4. Medical Product Outsourcing . 2007 . Ramsey, NJ : Rodman Publishing , July 8 issue, 119.
5. Downey , W. 2008 . " CMOs See Robust Growth, " Genetic Engineering and Biotechnology News , 28 ( 17 ) October 1 issue.
6. Lipp , E. 2008 . " Regenerative Therapies Gain Momentum, " Genetic Engineering and Biotechnology News , October 15. 52.
7. Medical Design Technology, Consumer Product Design , October 2008. 8.
8. Examples of these types of nanoparticles include: liposome, dendrimer, gold nanoshells, quantum dots, and fullerenes.
9. McGee , P. 2006 . " Delivering on Nano's Promise, " Drug Discovery & Development , October issue, 12-18 .
10. Target validation biomarkers, target compound interaction biomarkers, pharmacodynamic biomarkers (for effi cacy and safety), disease and disease modifi cation biomarkers, patient stratifi cation, and adaptive clinical trial design biomarkers.
11. Feuerstein , G. , et al. 2008 . " The Vastly Neglected Biomarkers Contributing to Early Clinical Development Failure, " American Pharmaceutical Review , May/June, 64-68 .